Managing symptoms and complications
- Acute kidney injury in hospital - NG175
- Acute myocardial injury - NG171
- Antibiotics for pneumonia in adults in hospital - NG173
- Critical care in adults - NG159
- Managing suspected or confirmed pneumonia in adults in the community - NG165
- Managing symptoms (including at the end of life) in the community - NG163.
Managing conditions that increase risk
- Children and young people who are immunocompromised - NG174
- Chronic kidney disease - NG176
- Community-based care of patients with chronic obstructive pulmonary disease (COPD) - NG168
- Cystic fibrosis - NG170
- Dermatological conditions treated with drugs affecting the immune response - NG169
- Gastrointestinal and liver conditions treated with drugs affecting the immune response - NG172
- Interstitial lung disease - NG177
- Rheumatological autoimmune, inflammatory and metabolic bone disorders - NG167
- Severe asthma - NG166.
Providing services during the pandemic
Rapid evidence summaries
These summaries cover:
- Acute use of non-steroidal anti-inflammatory drugs (NSAIDs) for people with or at risk of COVID-19 - ES23.
- Anakinra for COVID-19 associated secondary haemophagocytic lymphohistiocytosis - ES26
- Angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) in people with or at risk of COVID-19 - ES24
- Long-term use of non-steroidal anti-inflammatory drugs (NSAIDs) for people with or at risk of COVID-19 - ES25.
Medtech innovation briefings
These innovative technologies have been identified as being potentially useful during the COVID-19 pandemic:
Clinical knowledge summaries
These are concise, accessible summaries of current evidence for primary care professionals.
We've added some information about coronavirus - COVID-19 which is largely based on guidance from Public Health England.
Developing rapid guidelines
Rapid guidelines are developed with NHS England and NHS Improvement and a cross-speciality clinical group, supported by the specialist societies and royal colleges. They are developed quickly using a different approach to normal. We’re keeping them under review.
More information about other topics we're looking at and how they are prioritised is available.
Developing rapid evidence summaries
These look at whether certain medicines may increase the severity or length of COVID-19 illness.
We're working with the Medicines and Healthcare products Regulatory Agency. Together we'll facilitate rapid review of information and advice on the safety and efficacy of treatments for COVID-19.
We can provide free scientific advice for researchers developing novel diagnostics or therapeutics for COVID-19. You can also read our draft guide on clinical evidence generation for COVID-19 medicines.
During this crisis we've had to adjust our normal methods of producing guidance and advice. Find out which topics we'll publish as planned.
For our COVID-19 products we have waived our normal licensing requirements for international reuse or reproduction of our content.
Email us with any feedback about our rapid guidelines and evidence summaries.